President Trump has picked Dr. Heidi Overton, a deputy director at the White House Domestic Policy Council, to lead the Food and Drug Administration, teeing up a Senate confirmation fight over her past writings on abortion medication and her hand in reshaping childhood vaccine policy. The nomination fills a post that has sat empty since May, when Dr. Marty Makary resigned as commissioner amid clashes over e-cigarettes, rare disease drug reviews and medication abortion.
Overton, a medical doctor who trained at the University of New Mexico, has spent the past year working on several of Trump's second-term health initiatives, according to Boston 25 News. She has appeared alongside the president to unveil drug-company deals meant to lower prices, and she stood in the Oval Office on August 10 as Trump signed an executive order directing the Department of Health and Human Services to pursue changes to childhood immunizations, including splitting the combined measles, mumps and rubella vaccine into three separate shots, according to AJMC. Major medical associations had advised against separating the combined MMR vaccine, and decades of scientific research have found no link between vaccines and autism spectrum disorder, per the same account.
Before joining the Domestic Policy Council in 2025, Overton served as chief policy officer at the America First Policy Institute, where in a 2023 policy brief she described the abortion medication mifepristone as “teleabortion” and “abortion-on-demand,” urging Congress to regulate the drug more strictly, according to The Guardian. If confirmed, Overton could roll back FDA rules that made the abortion pill more accessible, Boston 25 News reports, a shift that would ripple through the more than 23 million women living in states with abortion restrictions, per The Guardian's reporting.
A Search That Passed Over Oncology and Military Health Leaders
The White House's search for a new commissioner had narrowed to a shortlist that included oncologist Dr. Jeff Vacirca and Pentagon health official Stephen Ferrara before Overton emerged as the pick, with her nomination bolstered by strong backing from White House Chief of Staff Susie Wiles and Agriculture Secretary Brooke Rollins, according to BioPharma Dive's reporting cited in the dossier. Overton holds an MD from UNM and a PhD in clinical investigation from Johns Hopkins University, where she was appointed to the university's board of regents in her final years of medical school and later co-authored academic research with Makary himself, her eventual predecessor at the agency.
In the three months between Makary's resignation and Overton's nomination, attorney Kyle Diamantas, previously the FDA's Deputy Commissioner for Human Foods and a former Jones Day partner, ran the agency as acting commissioner, having been appointed to the interim role on May 15. Under that interim leadership, the FDA on August 10 proposed a rule requiring food manufacturers to formally notify federal regulators whenever they designate a substance as Generally Recognized as Safe, converting what had been a voluntary notification framework into a mandatory one, according to Holland & Knight.
Unfinished Business Left By Makary's Exit
Makary's departure left several FDA projects unresolved, including an effort with the White House to finalize a definition of ultraprocessed foods, a review of widely used antidepressants for possible risks during pregnancy, and questions over the effectiveness of Covid-19 vaccines after the agency blocked publication of related research, per Boston 25 News. During his 13 months as commissioner, Makary had also announced programs meant to streamline or accelerate drug approvals even as the FDA rejected or reversed a number of biotech drugs intended for rare diseases.
The agency has also been navigating competing pressures from Trump's preferences, Republican anti-regulatory interests and Health and Human Services Secretary Robert F. Kennedy Jr.'s anti-corporate posture, the outlet reports. Under Kennedy, the FDA opened the door to allowing more unauthorized electronic cigarettes and nicotine pouches onto the market and set up extra hurdles for vaccine testing, even as Kennedy-selected federal health advisers recommended easing access to several peptides that FDA scientists had warned were not shown to be safe or effective.
Staff Turnover and Ongoing Food Safety Cases
The leadership churn has extended beyond the commissioner's office. Dr. Vinay Prasad stepped down as the FDA's vaccine and biotech chief in April, and Dr. Tracy Beth Hoeg was later replaced as the agency's acting drug center director, a departure Hoodline previously reported came amid broader upheaval following Makary's resignation. Meanwhile the agency has kept up its core food safety work, investigating a multistate salmonella outbreak linked to jalapeño peppers and a cyclospora outbreak tied to tainted iceberg lettuce, per Boston 25 News.
Overton's nomination now heads to the Senate Health, Education, Labor and Pensions Committee, chaired by Republican Senator Bill Cassidy of Louisiana, who has publicly criticized some of Trump's actions on vaccinations, including his concerns after the Oval Office order modifying the childhood vaccine schedule. Because the commissioner position requires Senate confirmation under 21 U.S.C. § 393(d) — a requirement Congress added in 1988 to strengthen oversight of the post — Overton will need approval from a narrowly Republican-led Senate and will face questions from Cassidy's committee before she can take the job leading an agency whose regulatory reach touches roughly 20 cents of every consumer dollar spent in the United States, according to BioPharma Dive.
.jpg){kind=link}